Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12345678910111213...208209»
  • ||||||||||  HRS-5965 / Jiangsu Hengrui Pharma, Soliris (eculizumab) / AstraZeneca
    DEFINING THE ERYTHROBLASTIC ISLAND MACROPHAGE AND ITS INVOLVEMENT IN THE PATHOGENESIS AND ANEMIC STATE OF LOW-RISK MYELODYSPLASTIC SYNDROMES () -  May 12, 2026 - Abstract #EHA2026EHA_3920;    
    Table 1. Efficacy and Safety Outcomes HRS-5965(N=40)Eculizumab (N=36)Difference(95% CI)P valuePrimary endpoints Hb ?12 g/dL#, n (%)28 (70.0%)4 (11.1%)57.4% (39.6-75.2)Secondary endpoints Hb increase ?2 g/dL#, *, n (%)38 (95.0%)20 (55.6%)39.2% (20.9-57.4)Transfusion-free (after Wk 2), n (%)40 (100%)31 (86.1%)13.7% (2.4-24.9)0.0149Mean Hb change from baseline#, g/dL,LS Mean (SE)5.47 (0.31)2.86 (0.32)2.61 (1.72-3.49)FACIT-Fatigue score improvement#,LS Mean (SE)8.62 (0.70)4.43 (0.74)4.19 (2.15-6.23)0.0001Reticulocyte count change from baseline#, x10?/L, LS Mean (SE)-118.97 (9.41)42.40 (9.93)-161.37 (-188.62, -134.13)Safety MAVEs, n (%)00
  • ||||||||||  Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    GLUCOCORTICOID INDUCED LEUCINE ZIPPER REGULATES HEMATOPOIETIC STEM CELL QUIESCENCE VIA REPRESSION OF MTOR-MEDIATED ACTIVATION (Hall A) -  May 12, 2026 - Abstract #EHA2026EHA_3548;    
    This multicenter study demonstrates for the first time that, in patients undergoing autologous HSCT, hetrombopag is associated with significantly faster neutrophil and platelet engraftment compared with eltrombopag, with a favorable safety profile. Hetrombopag may represent a more effective option for promoting hematopoietic recovery following autologous stem cell transplantation.
  • ||||||||||  golidocitinib (DZD4205) / Dizal Pharma, Itari (linperlisib) / Shanghai YingLi Pharma
    SYNERGISTIC TARGETING OF JAK-STAT AND PI3K PATHWAYS BY GOLIDOCITINIB AND LINPERLISIB IN T-ALL/LBL: INVOLVEMENT OF RAG1/2 REGULATION () -  May 12, 2026 - Abstract #EHA2026EHA_3169;    
    Given its role in DNA damage response, the combination-induced upregulation of RAG1/2 may enhance genomic instability to sensitize tumor cells and serve as a mechanistic marker or therapeutic target in T-ALL/LBL. Based on this dual modulation of the TP53 and PI3K-AKT signaling axes, a "pro-apoptotic and anti-survival" strategy is established, offering a promising therapeutic avenue for T-ALL/LBL.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    EFFICACY AND SAFETY OF FLUMATINIB COMBINED WITH CHEMOTHERAPY IN NEWLY DIAGNOSED ADULT PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (Hall A) -  May 12, 2026 - Abstract #EHA2026EHA_3036;    
    CRISPR-Cas9 dropout screens have shown that BRD4 and histone acetyltransferase EP300 are dependencies in post-MPN sAML cells, supporting the rationale to inhibit both proteins with a single targeted agent.Aims: To determine the effects of dual BET/HAT inhibitor monotherapy and combination with JAK inhibitor or CDK7 inhibitor in post-MPN sAML cells that are sensitive or persister/resistant to JAK or BET inhibitor.We determined the effects of treatment with the dual BET/HAT inhibitor EP31670 (EP) on the transcriptome, proteome, cell cycle and viability of post-MPN sAML cells...Notably, co-treatment with EP and ruxolitinib induced synergistic lethality in cultured and patient-derived (PD) post-MPN sAML...We also determined that co-treatment with EP and CDK7i SY-5609 (SY) was synergistically lethal in sAML cell lines including those resistant to JAKi or BETi, as well as PD MPN-sAML cells... These findings demonstrate promising preclinical activity of EP against MPN-sAML cells and strongly support the rationale to further evaluate the efficacy of EP-based combinations against advanced MPN with excess blasts or MPN-sAML.
  • ||||||||||  Iclusig (ponatinib) / Takeda, Nailike (olverembatinib) / Takeda, Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    CURRENT STATUS SURVEY OF TOLERABILITY BURDEN OF FIRST- OR SECOND-LINE TKI THERAPY IN CHINESE PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) () -  May 12, 2026 - Abstract #EHA2026EHA_2578;    
    The high prevalence of multiple, persistent AEs not only compromised patients' QoL and work productivity but also drove increased healthcare utilization, resulting in considerable clinical and economic burden. These findings highlight an urgent need for treatment options with favorable tolerability profiles to mitigate the impact of AEs and safeguard quality of life in patients with CML.Table 1.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    ELN RECOMMENDED RESPONSE MILESTONES PREDICT SURVIVAL AND DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING SECOND-GENERATION TYROSINE KINASE INHIBITOR () -  May 12, 2026 - Abstract #EHA2026EHA_2545;    
    However, the significance of the ELN recommended response milestones in the context of (2G) TKI remains poorly defined.Aims: A retrospective study was designed to analyze the impact of the ELN recommended response milestones on survival outcomes and deep molecular responses (DMR) in patients with CML-CP receiving 2G TKI.Patients aged ?18 years with CML-CP receiving nilotinib, dasatinib or flumatinib as the first-line therapy at Peking University People's Hospital between 2002 and 2025 were retrospectively reviewed... For patients receiving 2G-TKI, the ELN 3-month treatment milestone is an robust predictor of CML-related OS, whereas the ELN milestones at 3, 6, and 12 months all serve as predictive factors for TFS and DMR.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    REAL-WORLD ANALYSIS OF FIRST-LINE TKI USE IN CML-CP: A 16-YEAR MULTICENTER EXPERIENCE () -  May 12, 2026 - Abstract #EHA2026EHA_2542;    
    However, in real-world practice, treatment discontinuation limited the sustainability of second-generation TKI therapy, resulting in no significant improvement in 5-year EFS compared with imatinib. These findings highlight the dissociation between efficacy and treatment persistence with second-generation TKIs in routine clinical settings, underscoring the need for novel agents that integrate high efficacy with improved safety and tolerability profiles.This research was supported by the National Natural Science Foundation of China (No.
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    HETROMBOPAG FOR THROMBOCYTOPENIA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE SINGLE-CENTER STUDY () -  May 12, 2026 - Abstract #EHA2026EHA_2529;    
    The CRG mutation profiles differed between AYA and non-AYA populations. Notably, first-line treatment with second-generation TKIs conferred a greater efficacy advantage in AYA patients,with comparable median times to MMR among dasatinib, nilotinib, and flumatinib.This research was supported by the National Natural Science Foundation of China (No.
  • ||||||||||  azacitidine / Generic mfg.
    A FOUR-GENE STEMNESS SCORE PREDICTS HMA RESISTANCE AND IDENTIFIES RATIONAL 5-AZACITIDINE COMBINATION STRATEGIES IN MYELODYSPLASTIC SYNDROMES () -  May 12, 2026 - Abstract #EHA2026EHA_2528;    
    Whether the initial use of a second-generation (2G) TKI can improve the success rate of TFR remains an unanswered question.Aims: To identify covariates associated with TFR success following TKI discontinuation.In the multicenter, retrospective, real-word study, data on the outcomes of TKI discontinuation in the adults with chronic-phase CML (CML-CP) who had a imatinib therapy duration ?5 years or a 2G-TKI [nilotinib, dasatinib, or flumatinib] therapy duration ?3 years and a sustained deep molecular response (DMR) ?2 years from 17 Chinese hospitals were analyzed. The real-world multicenter retrospective study revealed that the front-line treatment with a 2G-TKI improved the success rate of TFR in CML-CP patients beyond achieving a longer DMR.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Ibrance (palbociclib) / Pfizer, Epidaza (chidamide) / Chipscreen
    TGF-BETA SIGNALING IS DEREGULATED BY TYPE I CALRETICULIN MUTATIONS IN MYELOPROLIFERATIVE NEOPLASM () -  May 12, 2026 - Abstract #EHA2026EHA_1608;    
    The enrichment of specific cell cycle (CCND3/CDKN2A), epigenetic (CREBBP/KMT2D/DNMT3A), and kinase (PIK3R1) mutations presents profound therapeutic opportunities. Integrating genome-driven precision medicine
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, TERN-701 / Terns Pharma
    THE SAFETY, TOLERABILITY, AND EFFICACY OF HS-10382 COMBINED WITH FLUMATINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CML: A PHASE 1B STUDY () -  May 12, 2026 - Abstract #EHA2026EHA_1543;    
    For the first time, our analysis identified a genome-wide significant locus associated with increased ATE risk in IMiD-treated MM patients and a potential link to a putative binding site for IKZF1, a key degradation target of IMiDs, which warrants further validation. Our results support a role for common germline variation in ATE susceptibility and may open a perspective on using germline genetics for individualising side effect risk profiles for patients on long-term anti-MM therapy.
  • ||||||||||  AiTan (rivoceranib) / Elevar Therapeutics
    Review, Journal:  Apatinib mesylate in the treatment of advanced triple-negative breast cancer. (Pubmed Central) -  May 8, 2026   
    The correct and complete study information can be found under identifier NCT07234318. This review examines the role of apatinib in treating TNBC and explores its potential mechanisms when combined with chemotherapeutic agents and ICIs for advanced TNBC in the era of immunotherapy.
  • ||||||||||  Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
    Biomarker, Enrollment closed, Trial completion date, Trial primary completion date:  A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (clinicaltrials.gov) -  May 7, 2026   
    P4,  N=378, Active, not recruiting, 
    https://clinicaltrials.gov/study/NCT03986515, identifier NCT03986515. Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2026 --> Jul 2026
  • ||||||||||  ribupatide injection (HRS9531 injection) / Kailera Therapeutics
    Trial completion, Trial completion date, Trial primary completion date:  HRS9531-105: A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects (clinicaltrials.gov) -  May 5, 2026   
    P1,  N=32, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2026 --> Jul 2026 Trial completion date: Jul 2024 --> Sep 2025 | Trial primary completion date: Jul 2024 --> Sep 2025 | Recruiting --> Completed
  • ||||||||||  Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
    New trial, Real-world evidence:  Real-World Assessment of VEVYE (clinicaltrials.gov) -  May 5, 2026   
    P=N/A,  N=50, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / Elevar Therapeutics, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Apatinib and Adebrelimab Exhibit Synergistic Antitumor effects in Small Cell Lung Cancer: An In Vitro Study. (Pubmed Central) -  May 5, 2026   
    Trial completion date: Jul 2024 --> Sep 2025 | Trial primary completion date: Jul 2024 --> Sep 2025 | Recruiting --> Completed In summary, the combination of Apa and Ade represented a promising innovative therapeutic strategy for SCLC.